CBU
APGE icon

CIBC Bancorp USA’s Apogee Therapeutics APGE Stock Holding History

CIBC Bancorp USA’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$331K Buy
+2,495
New +$225K ﹤0.01% 1484

Other funds holding APGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

CIBC Bancorp USA's APGE Position: Q2 2026 in Review

CIBC Bancorp USA opened a new position in Apogee Therapeutics (APGE) in Q2 2026: 2,495 shares worth $331K. The stake represents ﹤0.01% of the portfolio and ranks #1484 among its holdings.

258 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • CIBC Bancorp USA held 2,495 shares of Apogee Therapeutics worth $331K as of Q2 2026.
  • Apogee Therapeutics was a new CIBC Bancorp USA position in Q2 2026.
  • Apogee Therapeutics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q2 2026, its #1484 holding.
  • 258 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on CIBC Bancorp USA's 13F filing for Q2 2026, filed 13 Aug 2026.